Evidence map›Paper›PMID 37876937›Full record

ArticleFrontiers in immunology2023

Novel frameshift variants expand the map of the genetic defects in IRF2BP2.

José María García-Aznar, Emilia Maneiro Pampín, Maite García Ramos, María José Acuña Pérez, Nerea Paz Gandiaga, Laura Minguell Domingo, Olga Calavia, Pere Soler-Palacin, Roger Colobran, Erika M Novoa Bolívar and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Case Report: NovelFrontiers in immunology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

José María García-AznarDepartment of Immunology, Health in Code, A Coruña, Galicia, Spain.
Emilia Maneiro PampínDepartment of Immunology, Health in Code, A Coruña, Galicia, Spain.
Maite García RamosDepartment of Immunology, Health in Code, A Coruña, Galicia, Spain.
María José Acuña PérezDepartment of Immunology, Health in Code, A Coruña, Galicia, Spain.
Nerea Paz GandiagaGenetics Division, Universitary Hospital Marqués de Valdecilla, Santander, Canatabria, Spain.
Laura Minguell DomingoPediatrics Division, Universitary Hospital Arnau de Vilanova, Lleida, Catalonia, Spain.
Olga CalaviaPediatrics Division, Hospital Joan XXIII, Tarragona, Catalonia, Spain.
Pere Soler-PalacinPediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital, Barcelona, Catalonia, Spain.
Roger ColobranImmunology Division, Vall d'Hebron University Hospital (HUVH), Barcelona, Catalonia, Spain.
Erika M Novoa BolívarImmunology Division, Universitary Hospital Virgen de la Arrixaca, Murcia, Spain.
Javier Gonzalo Ocejo VinyalsImmunology Division, Universitary Hospital Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain.
Hospital Universitari Arnau de Vilanova · ESHospital Universitari Joan XXIII de Tarragona · ESHospital Universitario Virgen de la Arrixaca · ESInstituto de Investigación Marqués de Valdecilla · ESMarqués de Valdecilla University Hospital · ESUniversitat Autònoma de Barcelona · ESVall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: At present, the knowledge about disease-causing mutations in IRF2BP2 is very limited because only a few patients affected by this condition have been reported. As previous studies have described, the haploinsufficiency of this interferon transcriptional corepressors leads to the development of CVID. Very recently, a more accurate phenotype produced by truncating variants in this gene has been defined, manifesting CVID with gastrointestinal inflammatory symptoms and autoimmune manifestations. Methods: We analyzed 5 index cases with suspected primary immunodeficiency by high throughput sequencing. They were submitted for a genetic test with a panel of genes associated with immune system diseases, including IRF2BP2. The screening of SNVs, indels and CNVs fulfilling the criteria with very low allelic frequency and high protein impact, revealed five novel variants in IRF2BP2. In addition, we isolated both wild-type and mutated allele of the cDNA from one of the families. Results: In this study, we report five novel loss-of-function (LoF) mutations in IRF2BP2 that likely cause primary immunodeficiency, with CVID as more frequent phenotype, variable expression of inflammatory gastrointestinal features, and one patient with predisposition of viral infection. All identified variants were frameshift changes, and one of them was a large deletion located on chromosome 1q42, which includes the whole sequence of IRF2BP2, among other genes. Both Conclusions: We describe novel variants in a delimited low-complex region, which may be considered a hotspot in IRF2BP2. Moreover, this is the first time that a large CNV in IRF2BP2 has been reported to cause CVID. The distinct mechanisms than LoF in IRF2BP2 could cause different phenotype compared with the mainly described. Further investigations are necessary to comprehend the regulatory mechanisms of IRF2BP2, which could be under variable expression of the disease.

Indexed as

Frameshift MutationGenetic TestingDNA-Binding ProteinsGenotypeHumansLoss of Function MutationPhenotypeTranscription FactorsDNA-Binding ProteinsIRF2BP2 protein, humanTranscription FactorscolitisCVIDIRF2BP2loss-of-function mutationsprimary immunodeficiency

Identifiers

PMID37876937
PMCPMC10593445
OpenAlexW4387461441

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.